DE602004012318D1 - Crf-rezeptorantagonisten und diese betreffende verfahren - Google Patents

Crf-rezeptorantagonisten und diese betreffende verfahren

Info

Publication number
DE602004012318D1
DE602004012318D1 DE602004012318T DE602004012318T DE602004012318D1 DE 602004012318 D1 DE602004012318 D1 DE 602004012318D1 DE 602004012318 T DE602004012318 T DE 602004012318T DE 602004012318 T DE602004012318 T DE 602004012318T DE 602004012318 D1 DE602004012318 D1 DE 602004012318D1
Authority
DE
Germany
Prior art keywords
sub
crf receptor
receptor antagonists
methods
crf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602004012318T
Other languages
English (en)
Other versions
DE602004012318T2 (de
Inventor
Zhiyong Luo
John Edward Tellew
John Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocrine Biosciences Inc
SB Pharmco Puerto Rico Inc
Original Assignee
Neurocrine Biosciences Inc
SB Pharmco Puerto Rico Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocrine Biosciences Inc, SB Pharmco Puerto Rico Inc filed Critical Neurocrine Biosciences Inc
Publication of DE602004012318D1 publication Critical patent/DE602004012318D1/de
Application granted granted Critical
Publication of DE602004012318T2 publication Critical patent/DE602004012318T2/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602004012318T 2003-12-22 2004-12-20 Crf-rezeptorantagonisten und diese betreffende verfahren Expired - Fee Related DE602004012318T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53203203P 2003-12-22 2003-12-22
US532032P 2003-12-22
PCT/IB2004/004242 WO2005063749A1 (en) 2003-12-22 2004-12-20 Crf receptor antagonists and methods relating thereto

Publications (2)

Publication Number Publication Date
DE602004012318D1 true DE602004012318D1 (de) 2008-04-17
DE602004012318T2 DE602004012318T2 (de) 2009-03-12

Family

ID=34738734

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004012318T Expired - Fee Related DE602004012318T2 (de) 2003-12-22 2004-12-20 Crf-rezeptorantagonisten und diese betreffende verfahren

Country Status (7)

Country Link
US (1) US20070293508A1 (de)
EP (1) EP1697362B1 (de)
JP (1) JP2007515473A (de)
AT (1) ATE388150T1 (de)
DE (1) DE602004012318T2 (de)
ES (1) ES2303130T3 (de)
WO (1) WO2005063749A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308208D0 (en) 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2010096426A2 (en) * 2009-02-20 2010-08-26 Emory University Compounds, compositions, methods of synthesis, and methods of treatment
EP4074712A1 (de) * 2021-04-13 2022-10-19 Siegfried AG Verfahren zur synthese von 1,3-dihydro-imidazo[4,5-b]pyridin-2-on und/oder derivaten davon

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2180338T3 (es) * 1998-11-12 2003-02-01 Neurocrine Biosciences Inc Antagonistas del receptor de crf y metodos relacionados.
US6348466B1 (en) * 1998-11-12 2002-02-19 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
AU3958902A (en) * 2000-11-03 2002-05-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods relating thereto
WO2002064592A1 (en) * 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists

Also Published As

Publication number Publication date
DE602004012318T2 (de) 2009-03-12
EP1697362B1 (de) 2008-03-05
ES2303130T3 (es) 2008-08-01
EP1697362A1 (de) 2006-09-06
ATE388150T1 (de) 2008-03-15
WO2005063749A1 (en) 2005-07-14
JP2007515473A (ja) 2007-06-14
US20070293508A1 (en) 2007-12-20

Similar Documents

Publication Publication Date Title
ATE430746T1 (de) Crf-rezeptor-antagonisten und zugehörige verfahren
TW200626599A (en) CRF receptor antagonists and methods relating thereto
DK1129091T3 (da) Antagonister for CRF-receptorer og fremgangsmåder med relation dertil
TW200726765A (en) Triazolopyridine cannabinoid receptor 1 antagonists
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
MX2007012883A (es) Derivados de dihidrobenzofurano y usos de los mismos.
IS8502A (is) Azatvíhringja heteróhringir sem kannabínóíð-viðtakastillar
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
GB0504828D0 (en) Therapeutic agents
HK1068136A1 (en) Muscarinic antagonists
WO2007120647A3 (en) Compositions useful as inhibitors of voltage-gated sodium channels
WO2006044362A3 (en) N-sulfonylpiperidine cannabinoid receptor 1 antagonists
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
TR200102178T2 (tr) CRF reseptör antagonistleri ve bunlarla ilgili yöntemler.
DE60215637D1 (de) Tri- und tetraaza-acenaphthylen-derivate als crf-rezeptor-antagonisten
DE602004012318D1 (de) Crf-rezeptorantagonisten und diese betreffende verfahren
DE602004016328D1 (de) 2-imidazo-benzothiazole als adenosin-rezeptor liganden
DE60100811D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MXPA05012082A (es) Compuestos como antagonistas del receptor crf1.
DE60102231D1 (de) Crf rezeptor-antagonisten und darauf bezogene methoden
MXPA05010633A (es) Compuestos de pirrolo(1,2-b)piridazina y su uso como antagonistas del receptor de factor liberador de corticotropina-1.
GB0311349D0 (en) Therapeutic agents, compositions, preparations and uses
MXPA05010833A (es) Compuestos de pirrolo[1,2-b]piridazina y sus usos.

Legal Events

Date Code Title Description
8381 Inventor (new situation)

Inventor name: LUO, ZHIYONG, SAN DIEGO, CALIFORNIA 92130, US

Inventor name: TELLEW, JOHN EDWARD, SAN DIEGO, CALIFORNIA 921, US

Inventor name: WILLIAMS, JOHN, SAN DIEGO, CALIFORNIA 92130, US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee